Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.91 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL18010561 | 1.00 | TSHR (0.91) | TSHRTP53CYP2C9PDE4ALMNA | |
| Cadaverine Tartrate SCHEMBL80797 | 1.00 | TSHR (0.91) | TSHRTP53CYP2C9PDE4ALMNA | |
| Cadaverine Tartrate SCHEMBL8054016 | 1.00 | TSHR (0.91) | TSHRTP53CYP2C9PDE4ALMNA | |
| Cadaverine Tartrate SCHEMBL28556371 | 1.00 | TSHR (0.91) | TSHRTP53CYP2C9PDE4ALMNA | |
| Cadaverine Tartrate SCHEMBL8051107 | 1.00 | TSHR (0.91) | TSHRTP53CYP2C9PDE4ALMNA | |
| Cadaverine Tartrate SCHEMBL8766096 | 0.96 | TSHR (0.83) | TSHRTP53CYP2C9PDE4ALMNA | |
| Cadaverine Tartrate SCHEMBL7804043 | 0.96 | TSHR (0.83) | TSHRTP53CYP2C9PDE4ALMNA | |
| Cadaverine Tartrate SCHEMBL9550841 | 0.96 | TSHR (0.83) | TSHRTP53CYP2C9PDE4ALMNA | |
| Cadaverine Tartrate SCHEMBL4896930 | 0.96 | TSHR (0.83) | TSHRTP53CYP2C9PDE4ALMNA | |
| Cadaverine Tartrate SCHEMBL3707558 | 0.96 | TSHR (0.83) | TSHRTP53CYP2C9PDE4ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2429503-A1 | PHARMACEUTICAL SYSTEM FOR TRANS-MEMBRANE DELIVERY | Protein Delivery Solutions, LLC (US) | 2012-03-21 | — | — | EP | claimed |
| US-20100291160-A1 | PHARMACEUTICAL SYSTEM FOR TRANS-MEMBRANE DELIVERY | PROTEIN DELIVERY SOLUTIONS, LLC | 2010-11-18 | — | — | US | claimed |
| WO-2010132605-A1 | PHARMACEUTICAL SYSTEM FOR TRANS-MEMBRANE DELIVERY | PROTEIN DELIVERY SOLUTIONS, LLC (US) | 2010-11-18 | — | — | WO | claimed |
| US-5500668-A | INK JET PRINTING | XEROX CORPORATION (US) | 1996-03-19 | — | — | US | claimed |
| CN-116669434-A | Tin oxide electron transport layer modified in situ by aliphatic carboxylic acid potassium salt, high-performance photovoltaic cell and preparation method thereof | 武汉理工大学 | 2023-08-29 | — | — | CN | disclosed |
| US-9758462-B2 | Nitric acid oxidation processes | RIVERTOP RENEWABLES, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| CN-105916905-B | The manufacture method of Copolyacetal | 宝理塑料株式会社 | 2017-06-30 | — | — | CN | disclosed |
| US-9670124-B2 | Nitric acid oxidation process | RIVERTOP RENEWABLES, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160237016-A1 | OXIDATION PROCESS | RIVERTOP RENEWABLES INC (US) | 2016-08-18 | — | — | US | disclosed |
| US-9346736-B2 | Oxidation process | RIVERTOP RENEWABLES, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20160039735-A1 | NITRIC ACID OXIDATION PROCESSES | SILICON VALLEY BANK | 2016-02-11 | — | — | US | disclosed |
| EP-2970079-A1 | IMPROVED NITRIC ACID OXIDATION PROCESSES | Rivertop Renewables, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| CN-1713883-A | Oral composition having masked salt taste of salt | NOVILLE INC (CH) | 2005-12-28 | — | — | CN | disclosed |
| US-20050107621-A1 | 3-Hydroxy-3-(2-thienyl) propionamides and production method thereof, and production method of 3-amino-1-(2-thienyl)-1-propanols using the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2005-05-19 | — | — | US | disclosed |
| EP-1486493-A1 | 3-HYDROXY-3-(2-THIENYL)PROPIONAMIDE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND PROCESS FOR PRODUCING 3-AMINO-1-(2-THIENYL)-1-PROPANOL COMPOUND THEREFROM | Mitsubishi Chemical Corporation (JP) | 2004-12-15 | — | — | EP | disclosed |
| CN-1407883-A | Hair relaxer compositions using complexing agent activators | OREAL (FR) | 2003-04-02 | — | — | CN | disclosed |
| CN-1035828-C | Ployhydroxy fatty acid amide surfactants to enhance enzyme performance | PROCTER & GAMBLE (US) | 1997-09-10 | — | — | CN | disclosed |
| CN-1029010-C | Detergent compositions containing anionic surfactunts polyhydroxy fatty acid and magnesium | PROCTER & GAMBLE (US) | 1995-06-21 | — | — | CN | disclosed |
| US-5162378-A | Cetyl dimethicone copolyol, water, silicone, and alcohol; moisturizer, antiperspirant | REVLON CONSUMER PRODUCTS CORPORATION (US) | 1992-11-10 | — | — | US | disclosed |
| CN-1061036-A | The detergent composition that contains anion surfactant, polyhydroxy fatty acid amide and magnesium | PROCTER & GABMLE CO (US) | 1992-05-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107621-A1 | 3-Hydroxy-3-(2-thienyl) propionamides and production method thereof, and production method of 3-amino-1-(2-thienyl)-1-propanols using the same | APEH, AADAC, KMO | TSHR 879/4885TP53 4663/4885CYP2C9 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.